Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 7/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycinebetaine SCHEMBL1617824 | 0.86 | TSHR (0.42) | LMNATSHRALDH1A1APEX1BBOX1 | |
| Glycinebetaine SCHEMBL10425194 | 0.84 | TSHR (0.48) | LMNATSHRALDH1A1APEX1BBOX1 | |
| Glycinebetaine SCHEMBL31294426 | 0.84 | TSHR (0.46) | LMNATSHRALDH1A1APEX1BBOX1 | |
| Glycinebetaine SCHEMBL9281697 | 0.83 | TSHR (0.55) | LMNATSHRALDH1A1APEX1BBOX1 | |
| Glycinebetaine SCHEMBL8651387 | 0.83 | TSHR (0.48) | LMNATSHRALDH1A1APEX1BBOX1 | |
| Glycinebetaine SCHEMBL7739 | 0.83 | — | — | |
| Glycinebetaine SCHEMBL4900209 | 0.83 | — | — | |
| Glycinebetaine SCHEMBL8678519 | 0.83 | TSHR (0.53) | LMNATSHRALDH1A1APEX1BBOX1 | |
| Betaine SCHEMBL31467313 | 0.83 | — | — | |
| Glycinebetaine SCHEMBL2803780 | 0.83 | TSHR (0.53) | LMNATSHRALDH1A1APEX1BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115671375-A | Emulsion-enhanced viscosity-increasing drug-loaded hydrogel dressing and preparation method thereof | 中国人民解放军空军军医大学 | 2023-02-03 | — | — | CN | claimed |
| CN-109438716-B | Stable zwitterion surface modified nano-silver and preparation method and application thereof | 成都博岩科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| WO-2024068443-A1 | GRAFT POLYARYLETHER COPOLYMERS | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024052192-A1 | FLUOROPOLYMER MEDICAL DEVICES | UNOMEDICAL A/S (DK) | 2024-03-14 | — | — | WO | disclosed |
| CN-115671375-A | Emulsion-enhanced viscosity-increasing drug-loaded hydrogel dressing and preparation method thereof | 中国人民解放军空军军医大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-115671375-A | Emulsion-enhanced viscosity-increasing drug-loaded hydrogel dressing and preparation method thereof | 中国人民解放军空军军医大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-110655817-B | Long-acting antibacterial multifunctional coating with enhanced stability and preparation and application thereof | 四川大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-109438716-B | Stable zwitterion surface modified nano-silver and preparation method and application thereof | 成都博岩科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-110655817-A | Long-acting antibacterial multifunctional coating with enhanced stability and preparation and application thereof | 四川大学 | 2020-01-07 | — | — | CN | disclosed |
| US-20190040257-A1 | Low Energy, Cold Process Formulation Aid | JEEN INTERNATIONAL CORPORATION (US) | 2019-02-07 | — | — | US | disclosed |
| US-10138374-B2 | Low energy, cold process formulation aid | JEEN INTERNATIONAL CORP. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2555759-B1 | LOW ENERGY, COLD PROCESS FORMULATION AID | JEEN INT CORP (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20140336308-A1 | Low Energy, Cold Process Formulation Aid | JEEN INTERNATIONAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2585173-A2 | LOW-IRRITATING, CLEAR CLEANSING COMPOSITIONS WITH RELATIVELY LOW PH | Johnson & Johnson Consumer Companies Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2555759-A1 | LOW ENERGY, COLD PROCESS FORMULATION AID | Jeen International Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8299162-B2 | Low energy, cold process formulation aid | JEEN INTERNATIONAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011163467-A2 | LOW-IRRITATING, CLEAR CLEANSING COMPOSITIONS WITH RELATIVELY LOW PH | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011127311-A1 | LOW ENERGY, COLD PROCESS FORMULATION AID | JEEN INTERNATIONAL CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110250249-A1 | Low Energy, Cold Process Formulation Aid | MATEU JUAN R | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040257-A1 | Low Energy, Cold Process Formulation Aid | CPNE4, CUTA, FCER2 | LMNA 2418/4885TSHR 3302/4885ALDH1A1 1167/4885 |
| US-10138374-B2 | Low energy, cold process formulation aid | CPNE4, CUTA, FCER2 | LMNA 2418/4885TSHR 3302/4885ALDH1A1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.